Not Telling Patients Their Cancer Diagnosis in Egypt: Is It Associated With Less Anxiety and Depression and Better Quality of Life?

Samy A. Alsirafy, MBCh, MSc, MD; Hadeer I. Abdel-Aziz, MBCh, MSc; Hesham H. Abdel-Aal, MBCh, MSc, MD; Wessam A. El-Sherief, MBCh, MSc, MD; and Dina E. Farag, MBCh, MSc, MD

**PURPOSE** In many countries, including Egypt, it is still believed that not telling patients their cancer diagnosis is associated with less psychological morbidity. This study was conducted to explore whether not telling Egyptian patients their cancer diagnosis is associated with less anxiety and depression and better quality-of-life (QoL) or not.

**METHODS** A cross-sectional observational study was conducted in two Egyptian cancer care facilities and included 292 adult patients with cancer of whom 197 (67%) were aware of their diagnosis and 95 (33%) were unaware. The Hospital Anxiety and Depression Scale (HADS) was used to assess anxiety and depression and the Functional Assessment of Cancer Therapy-General 7 questionnaire to assess QoL.

**RESULTS** Patients unaware of their cancer diagnosis were significantly more likely to be less educated, with no family history of cancer, interviewed within 6 months of cancer diagnosis, diagnosed with a cancer other than breast and colorectal cancer, in a poorer performance status, and with no history of anticancer treatment. There was no significant difference between unaware and aware patients in the scores of HADS-Anxiety (median [interquartile range (IQR)] = 6 [3-11] and 7 [4-11], P = .203), HADS-Depression (median [IQR] = 8 [4-12] and 8 [4-11], P = .64), and Functional Assessment of Cancer Therapy-General 7 (median [IQR] = 16 [12-20] and 16 [11-21], P = .754). In multiple regression analysis with adjustment, diagnosis unawareness did not associate significantly with anxiety, depression, and QoL (P = .394, .662, and .845, respectively).

**CONCLUSION** The results of the current study confirm that not telling adult patients their cancer diagnosis is not associated with less anxiety and depression nor better QoL.

**INTRODUCTION** Although the disclosure of cancer-related information to patients is a usual practice in western countries mainly, it is still an issue of debate in many other countries including the Arab ones such as Egypt.

Those who argue for truth-telling call for respecting the ethical principles autonomy and beneficence. In the context of autonomy, cancer-related information is disclosed honestly to patients with cancer because the majority of them prefer to know this information, even in countries where nondisclosure is considered an acceptable practice. Not telling the truth to patients represents an obstacle to making an informed consent and may lead patients to take unwise and possibly harmful decisions.

Furthermore, many studies found that meeting the information needs of patients with cancer is associated with less anxiety and depression and better quality-of-life (QoL).

On the other hand, opponents arguing against truth-telling justify their viewpoint according to the non-maleficence principle as they believe that the harms caused by truth-telling would outweigh benefits. A main cause behind not telling patients the truth is the fear of causing psychological morbidity to them and the assumption that unaware patients have less psychological distress.

A number of studies, mainly from Mediterranean and Asian countries, explored the association between the awareness of diagnosis and psychological morbidity in patients with cancer. The evidence obtained from these studies is conflicting with some of the results supporting the hypothesis that unaware patients have less psychological morbidity and some others rejecting it.

The aim of this study was to examine the relationship between cancer diagnosis awareness and the psychological morbidity and QoL among Egyptian patients.
with cancer. The current study adds to the available evidence by conducting it in a different culture where non-disclosure is practiced. In addition, the study was designed to avoid some of what may be considered weaknesses in previous studies.

**METHODS**

This cross-sectional observational study was conducted in two Egyptian cancer centers, one in Cairo (Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine, Kasr Al-Ainy School of Medicine, Cairo University) and the other in Damietta in North Egypt (Damietta Cancer Center, Ministry of Health). Although Cairo, the capital of Egypt, is urban with a population of 10 million, Damietta is a small partially urban governorate located in the Nile Delta at the Mediterranean Sea with a population of < 2 million.

The protocol of the study was approved by the Ethics Committee of Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine. All participants signed (or fingerprinted) written informed consent before participation.

Adult (older than 18 years) Arabic-speaking patients with histologically confirmed diagnosis of cancer and no communication barriers were included in the study. Patients residing in villages were considered from rural areas. A purposive convenience sampling method was used to recruit participants.

**Assessment of Cancer Diagnosis Awareness**

To determine the awareness of cancer diagnosis, patients were asked to answer the following question: *What is the diagnosis of the disease that you are treated for here or has been diagnosed on the basis of the tests?* Those who answered the question using the words cancer or malignant were considered aware. Those who answered by saying tumor were further asked about the nature of the tumor and were considered aware if they said that it is a malignant tumor.

**Assessment of Anxiety and Depression**

Anxiety and depression were assessed using the Hospital Anxiety and Depression Scale (HADS) which comprises two subscales, one for anxiety and the other for depression. Each subscale includes seven questions with a 4-point Likert scale (from 0 to 3), and the final score ranges from 0 to 21. Patients were grouped according to the subscale score into normal (0-7), borderline abnormal (8-10), and abnormal (11-21). For imputing missing HADS items, subject's subscale mean was used. The Arabic version of HADS was used in this study.

**Assessment of QoL**

The QoL of patients was measured using the Arabic version of the Functional Assessment of Cancer Therapy-General 7 (FACT-G7). The FACT-G7 is an abbreviated version of the FACT-G health-related QoL questionnaire. It is a seven-item scale which is answered on a 5-point Likert scale with a score ranging from 0 to 4. The total FACT-G7 score ranges from 0 to 28 with the higher scores indicating better QoL. Scoring was according to the guidelines provided by the tool developer.

**Data Collection**

Patients were interviewed to complete the Arabic versions of the HADS and FACT-G7 questionnaires in addition to sociodemographic data collection. Disease and treatment information were collected from the patients’ files.

**Sample Size**

The primary end point of the study was to detect a difference in the total HADS score between aware and unaware patients. Secondary end points included the difference in QoL measured by the FACT-G7 between the two groups, the relation between variables and awareness of cancer diagnosis and the relation between variables and HADS and FACT-G7 scores.

Statulator beta online software was used to calculate the sample size. The predetermined ratio of aware to unaware patients was 2:1. The sample size was calculated to detect a true difference in the mean HADS-total score of four points assuming a pooled standard deviation (SD) of nine points according to a study from Jordan, a neighbor country with largely similar culture. To achieve a power of 90%
| Variable                        | All Patients (N = 292) | Unaware (n = 95) | Aware (n = 197) | P*  |
|--------------------------------|------------------------|------------------|-----------------|-----|
| **Age, years**                 |                        |                  |                 |     |
| < 60                           | 235 (80.5)             | 71 (30.2)        | 164 (69.8)      | .0860 |
| ≥ 60                           | 57 (19.5)              | 24 (42.1)        | 33 (57.9)       |     |
| **Sex**                        |                        |                  |                 |     |
| Female                         | 177 (60.6)             | 50 (28.2)        | 127 (71.8)      | .0530 |
| Male                           | 115 (39.4)             | 45 (39.1)        | 70 (60.9)       |     |
| **Education level**            |                        |                  |                 |     |
| ≥ High school                 | 166 (56.8)             | 32 (19.3)        | 134 (80.7)      | < .0001 |
| < High school                 | 54 (18.5)              | 25 (46.3)        | 29 (53.7)       |     |
| Illiterate                    | 72 (24.7)              | 38 (52.8)        | 34 (47.2)       |     |
| **Marital status**            |                        |                  |                 |     |
| Married                       | 233 (79.8)             | 70 (30.0)        | 163 (70.0)      | .0710 |
| Other                         | 59 (20.2)              | 25 (42.4)        | 34 (57.6)       |     |
| **Having a job**              |                        |                  |                 |     |
| No                            | 144 (49.3)             | 45 (31.2)        | 99 (68.7)       | .6450 |
| Yes                           | 148 (50.7)             | 51 (36.8)        | 98 (66.2)       |     |
| **Urbanization**              |                        |                  |                 |     |
| Urban                         | 183 (62.7)             | 54 (29.5)        | 129 (70.5)      | .0830 |
| Rural                         | 109 (37.3)             | 41 (37.6)        | 68 (62.4)       |     |
| **Comorbidities**             |                        |                  |                 |     |
| No                            | 191 (65.4)             | 61 (31.9)        | 130 (68.1)      | .7650 |
| Yes                           | 101 (34.6)             | 34 (33.7)        | 67 (66.3)       |     |
| **Family history of cancer**  |                        |                  |                 |     |
| No                            | 194 (66.4)             | 76 (39.2)        | 118 (60.8)      | .0007 |
| Yes                           | 98 (33.6)              | 19 (19.4)        | 79 (80.6)       |     |
| **Duration since cancer diagnosis, months** | | | | |
| < 6                           | 139 (47.6)             | 59 (42.4)        | 80 (57.6)       | .0006 |
| ≥ 6                           | 153 (52.4)             | 36 (23.5)        | 117 (76.5)      |     |
| **Primary cancer**            |                        |                  |                 |     |
| Breast                        | 66 (22.6)              | 14 (21.2)        | 52 (78.8)       | .0432 |
| Colorectal                    | 56 (19.2)              | 15 (26.8)        | 41 (73.2)       |     |
| Head & neck                   | 21 (7.2)               | 7 (33.3)         | 14 (66.7)       |     |
| Hematological                 | 37 (12.7)              | 16 (43.2)        | 21 (56.8)       |     |
| Pancreas                      | 20 (6.8)               | 11 (55.0)        | 9 (45.0)        |     |
| Other                         | 92 (31.5)              | 32 (34.8)        | 60 (65.2)       |     |
| **Distant metastases (n = 256)** |                    |                  |                 |     |
| No                            | 144 (56.5)             | 45 (31.2)        | 99 (68.7)       | .9160 |
| Yes                           | 111 (43.5)             | 34 (30.6)        | 77 (69.4)       |     |
| **ECOG PS**                   |                        |                  |                 |     |
| 0-1                           | 178 (61.0)             | 45 (25.3)        | 133 (74.7)      | .0010 |
| 2-4                           | 114 (39.0)             | 50 (43.9)        | 64 (56.1)       |     |
| **Treatment plan**            |                        |                  |                 |     |
| Curative                      | 180 (61.6)             | 61 (33.9)        | 119 (66.1)      | .5320 |

(Continued on following page)
and a two-sided significance level of 5% and considering an exclusion rate of 20%, the required sample size was 192 for the aware group and 96 for the unaware (total 288). It was decided to recruit 300 patients.

### Statistical Methods

Categorical data were presented as number and percentage and continuous data as mean and SD or median and interquartile range (IQR). The chi-square test was used to test the significance of difference in proportions. The distribution of HADS and FACT-G7 data was tested for normality using the Shapiro-Wilk test. For abnormally distributed data, the Mann-Whitney test was used to determine the significance of difference between two groups and the Kruskal-Wallis test for more than two groups. The correlation between abnormally distributed data was tested using Spearman’s test. Multiple linear regression analysis with adjustment for age, sex, and variables related significantly to cancer diagnosis awareness or the studied outcomes (HADS-Anxiety, HADS-Depression, or FACT-G7) was performed to test the association of cancer diagnosis awareness with these outcomes. The significance of P value was set at <.05. Statistical analysis was performed using the MedCalc Statistical Software version 20.009 (MedCalc Software Ltd, Ostend, Belgium).

### RESULTS

Between December 2017 and September 2018, 300 patients were recruited. Eight (2.7%) patients were excluded because of missing data (five patients), no malignancy (two patients), and wrong completion of the HADS questionnaire (one patient). The final analysis included 292 patients; 197 (67.5%) were aware of diagnosis and 95 (32.5%) were unaware. The characteristics of patients with comparison between unaware and aware patients are presented in Table 1.

The most common primary cancer sites were breast, colorectum, hematological, head and neck, and pancreas as presented in Table 1. Less common tumors included sarcomas in 18 (6.2%), gynecological in 15 (5.1%), lung in 14 (4.8%), and others in 45 (15.4%). The anticancer treatment received was systemic chemotherapy in 201 (68.8%) patients, surgery in 159 (54.5%), radiotherapy in 85 (29.1%), and hormonal therapy in 30 (10.3%).

For the whole group of patients, the mean (SD) and median (IQR) scores were 7.5 (5.2) and 6 (3.3-11) for HADS-Anxiety, 8 (4.8) and 8 (4-11) for HADS-Depression, 15.5 (8.7) and 15 (9-22) for HADS-Total, and 15.6 (5.7) and 16 (11-20) for FACT-G7. HADS-Anxiety, HADS-Depression, and FACT-G7 values were abnormally distributed (Shapiro-Wilk test P < .001 for all).

The relationship between HADS-Anxiety, HADS-Depression, and FACT-G7 score and cancer diagnosis awareness and the other study variables is presented in Table 2. There was no significant difference in HADS-Anxiety, HADS-Depression, and FACT-G7 scores between aware and unaware patients. A significantly higher HADS-Anxiety score was associated with younger age, female gender and having no job. Significantly higher HADS-Depression score was associated with younger age, presence of distant metastases, poorer performance status, and palliative treatment plan. Similar to HADS-Depression, mainly disease-related variables were associated with significantly lower FACT-G7 scores.

The effect of cancer diagnosis awareness on studied outcomes in univariate and multivariate linear regression analyses for the whole group of patients is presented in Table 3. Unawareness of cancer diagnosis did not associate significantly with any of the outcomes. The analysis presented in Table 3 did not include distant metastases among the variables adjusted for because 37 patients had hematological malignancies. When the analysis was

---

**TABLE 1.** Characteristics of 292 Patients With Cancer and Comparison According to Their Cancer Diagnosis Awareness (Continued)

| Variable                      | All Patients (N = 292) | Unaware (n = 95) | Aware (n = 197) | P*  |
|-------------------------------|-----------------------|------------------|-----------------|-----|
| Received anticancer treatment |                       |                  |                 |     |
| No                            | 47 (16.1)             | 25 (53.2)        | 22 (46.8)       | .0010 |
| Yes                           | 245 (83.9)            | 70 (28.6)        | 175 (71.4)      |     |
| City of interview             |                       |                  |                 |     |
| Damietta                      | 156 (53.4)            | 53 (34.0)        | 103 (66.0)      | .5740 |
| Cairo                         | 136 (46.6)            | 42 (30.9)        | 94 (69.1)       |     |
| Setting of interview          |                       |                  |                 |     |
| Inpatient                     | 135 (46.2)            | 47 (34.8)        | 88 (65.2)       | .4410 |
| Outpatient                    | 157 (53.8)            | 48 (30.6)        | 109 (69.4)      |     |

Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status.

*Chi-square test.
| Variable                        | HADS-Anxiety | HADS-Depression | FACT-G7 |
|--------------------------------|--------------|-----------------|---------|
|                                | Median (IQR) | P               | Median (IQR) | P               | Median (IQR) | P               |
| Aware of cancer diagnosis      |              |                 |          |                 |              |                 |
| No                             | 6 (3.0-10.8) | .2030           | 8 (4.4-11.5) | .6400           | 16 (12.0-20.0) | .7540           |
| Yes                            | 7 (4.0-11.3) |                 | 8 (3.9-11.0) |                 | 16 (11.0-21.0) |                 |
| Age, years                     |              |                 |          |                 |              |                 |
| < 60                           | 7 (4.0-12.0) | .0001           | 8 (4.0-12.0) | .0490           | 15 (11.0-20.0) | .2130           |
| ≥ 60                           | 4 (2.0-7.0)  |                 | 6 (3.0-9.3)  |                 | 17 (12.8-21.0) |                 |
| Sex                            |              |                 |          |                 |              |                 |
| Female                         | 7 (4.0-12.0) | .0140           | 8 (4.0-11.0) | .5200           | 15 (11.0-20.0) | .3190           |
| Male                           | 5 (3.0-10.0) |                 | 8 (4.4-11.8) |                 | 16 (12.0-21.0) |                 |
| Education level                |              |                 |          |                 |              |                 |
| < High school                  | 6 (3.0-11.0) | .1790           | 7.5 (3.0-11.0) | .2840           | 17 (11.7-21.0) | .0270           |
| ≥ High school                  | 7 (4.0-12.0) |                 | 7 (4.0-11.0) |                 | 15 (11.0-19.0) |                 |
| Marital status                 |              |                 |          |                 |              |                 |
| Married                        | 7 (4.0-11.0) | .3850           | 8 (4.0-11.0) | .7830           | 16 (11.0-21.0) | .9350           |
| Other                          | 6 (3.0-10.0) |                 | 7 (4.0-12.0) |                 | 17 (12.0-20.0) |                 |
| Having a job                   |              |                 |          |                 |              |                 |
| Yes                            | 6 (3.0-10.0) | .0500           | 9 (5.0-11.9)  | .0790           | 16 (11.0-21.0) | .5750           |
| No                             | 7 (4.0-12.0) |                 | 7 (3.0-11.0)  |                 | 16 (11.8-20.0) |                 |
| Urbanization                   |              |                 |          |                 |              |                 |
| Urban                          | 6 (3.0-11.0) | .1520           | 8 (4.0-11.5)  | .9850           | 15 (11.0-20.8) | .3090           |
| Rural                          | 7 (4.0-11.0) |                 | 8 (4.2-11.0)  |                 | 17 (11.9-20.0) |                 |
| Comorbidities                  |              |                 |          |                 |              |                 |
| Yes                            | 5 (3.0-11.0) | .2850           | 8 (3.0-13.0)  | .8220           | 16 (10.0-21.0) | .5460           |
| No                             | 7 (4.0-11.0) |                 | 8 (4.0-11.0)  |                 | 16 (11.0-20.0) |                 |
| Family history of cancer       |              |                 |          |                 |              |                 |
| Yes                            | 8 (4.0-12.0) | .1070           | 8 (3.0-13.0)  | .8810           | 15.5 (11.0-20.0) | .3510         |
| No                             | 6 (3.0-11.0) |                 | 8 (4.0-11.0)  |                 | 16 (11.0-21.0) |                 |
| Time since cancer diagnosis, months |            |                 |          |                 |              |                 |
| < 6                            | 7 (3.0-11.0) | .8280           | 8 (4.0-12.0)  | .7710           | 15 (10.3-20.0) | .1050           |
| ≥ 6                            | 6 (4.0-11.0) |                 | 8 (4.0-11.0)  |                 | 17 (11.5-20.3) |                 |
| Primary cancer                 |              |                 |          |                 |              |                 |
| Breast                         | 7 (4.0-11.0) | .5960           | 7 (3.0-11.0)  | .1800           | 16 (11.0-20.0) | .5040           |
| Colorectal                     | 5.5 (3.0-11.0) | 9 (5.0-13.0) | 15 (11.0-22.0) | 13 (9.8-16.3) |                  |                 |
| Head & neck                    | 9 (4.8-14.0) |                 | 9 (7.8-13.3)  |                 | 17.5 (13.8-21.0) |                 |
| Hematological                  | 5 (3.8-9.0)  |                 | 7 (3.8-9.0)  |                 | 17.5 (13.8-21.0) |                 |
| Pancreas                       | 5.5 (3.5-10.5) | 6 (2.0-12.0) | 16.2 (10.5-20.0) |                 |                 |                 |
| Other                          | 7 (3.5-10.5) |                 | 8 (3.3-12.0)  |                 | 16 (12.8-20.0) |                 |
| Distant metastases (n = 254)   |              |                 |          |                 |              |                 |
| Yes                            | 7 (4.0-12.0) | .4340           | 9 (6.0-13.0)  | .0010           | 14 (10.0-18.8) | .0070           |
| No                             | 6 (3.0-11.0) |                 | 7 (3.0-11.0)  |                 | 16 (13.0-21.0) |                 |
| ECOG PS                        |              |                 |          |                 |              |                 |
| 0-1                            | 6 (3.0-12.0) | .7840           | 8 (4.0-10.0)  | .0070           | 17 (13.0-21.0) | .0040           |
| 2-4                            | 6 (4.0-10.0) |                 | 9 (4.2-13.0)  |                 | 14 (10.0-18.0) |                 |

(Continued on following page)
performed for solid tumor patients only with the inclusion of distant metastases in the models, the results were also insignificant (HADS-Depression: coefficient = –0.265, \(P = .713\) and FACT-G7: coefficient = 0.019, \(P = .982\)).

The frequency of HADS-Anxiety and HADS-Depression categories is presented in Table 4. The average FACT-G7 score differed significantly according to the categories of HADS-Anxiety and HADS-Depression and was lowest in anxiety and depression cases (Table 4). There was a significant negative correlation between the HADS-Anxiety and HADS-Depression scores and the FACT-G7 score (Spearman’s rho = –0.55 and –0.656, respectively, and \(P < .0001\) for both). The categories of HADS-Anxiety and HADS-Depression did not differ significantly according to cancer diagnosis awareness (Table 4).

**DISCUSSION**

In this study that included 292 Egyptian patients with cancer, anxiety and depression were not less and QoL was not better in those unaware of their cancer diagnosis when compared with those aware. To the best of our knowledge, this is the first study from an Arab country to address that issue. A number of studies from different countries investigated the relationship between cancer diagnosis awareness and psychological morbidity and provided conflicting evidence. Some studies from India,\(^{10}\) Turkey,\(^{13}\) and Iran\(^{14}\) found that cancer diagnosis awareness is associated with significant psychological morbidity when compared with unawareness. On the other hand, other studies from Italy,\(^{11}\) India,\(^{12}\) and China\(^{15,17}\) found no difference in psychiatric morbidity between aware and unaware patients. Furthermore, in one study from India, unaware patients had significantly higher anxiety and depression scores in bivariate analysis, but not in multivariate analysis.\(^{24}\) It is difficult to come out with a generalizable conclusion applicable to all cultures from these studies. In addition to cultural differences, there are variabilities in the population studied, sample size, method

### Table 2. HADS-Anxiety, HADS-Depression, and FACT-G7 Scores According to Cancer Diagnosis Awareness and the Other Study Variables (Continued)

| Variable                  | HADS-Anxiety | HADS-Depression | FACT-G7  |
|---------------------------|--------------|-----------------|----------|
|                           | Median (IQR) | Median (IQR)    | Median (IQR) | P | Median (IQR) | Median (IQR) | Median (IQR) | P |
| Treatment plan            |              |                 |           |    |              |              |           |    |
| Curative                  | 6 (3.0-11.0) | 7 (3.0-10.0)    | 16.5 (13.0-21.0) | .1760 | .0001 | .0130 |
| Palliative                | 7 (4.0-11.5) | 9 (6.0-13.0)    | 15 (10.5-19.0) |
| Anticancer treatment history |            |                 |           |    |              |              |           |    |
| Yes                       | 6 (3.0-11.0) | 8 (4.0-11.0)    | 16 (11.0-20.0) | .5680 | .8670 | .2800 |
| No                        | 8 (4.0-11.0) | 9 (3.6-11.8)   | 15 (10.3-20.8) |
| City of interview         |              |                 |           |    |              |              |           |    |
| Damietta                  | 6 (3.0-10.0) | 7.5 (4.0-10.3) | 16 (11.0-20.0) | .3590 | .1220 | .8460 |
| Cairo                     | 7 (4.0-11.5) | 9 (4.0-13.0)   | 16 (11.0-20.5) |
| Setting of interview      |              |                 |           |    |              |              |           |    |
| Inpatient                 | 6 (3.0-11.0) | 8 (4.1-12.0)   | 16.3 (11.0-20.8) | .9280 | .3350 | .3820 |
| Outpatient                | 6 (4.0-11.3) | 8 (3.9-11.0)   | 15 (11.0-20.0) |

Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; FACT-G7, Functional Assessment of Cancer Therapy-General 7; HADS, Hospital and Anxiety Depression Scale; IQR, interquartile range.

### Table 3. Regression Analysis to Determine the Effect of Cancer Diagnosis Awareness on Anxiety, Depression, and Quality of Life

| Outcome          | Univariate | Multivariate |
|------------------|------------|--------------|
|                  | Coefficient | Coefficient  |
| HADS-Anxiety     | 0.856      | 0.376        |
|                  | .184       | .600         |
| HADS-Depression  | –0.243     | –0.520       |
|                  | .685       | .426         |
| FACT-G7          | –0.264     | –0.084       |
|                  | .713       | .915         |

Abbreviations: FACT-G7, Functional Assessment of Cancer Therapy-General 7; HADS, Hospital and Anxiety Depression Scale.
of psychiatric morbidity assessment, and definition of cancer diagnosis awareness. For example, studies that showed a higher psychological morbidity among aware patients included relatively smaller sample size than those found no difference in the psychological morbidity according to awareness. Another example is the definition of cancer diagnosis awareness in these studies. Some studies considered a patient aware if he/she said that he/she has cancer or tumor. The current study was designed to avoid some of the pitfalls of other studies answering the same question. The sample size was calculated to determine a meaningful difference in the HADS score between aware and unaware patients. Furthermore, patients who said that they have a tumor were considered aware only when they define the malignant nature of the tumor. Those who stated that they have benign tumors were considered unaware.

The reason why patients unaware of their cancer diagnosis may experience a psychological morbidity equivalent to aware patients may be due to uncertainty about diagnosis, noninvolvement in care planning, and lack of convincing answers to health-related questions. In addition, lying to patients may result in losing their trust in health care professionals and their families.

On the basis of the findings of the current study and on the fact that the vast majority of Egyptian patients with cancer in Egypt prefers to be informed about their cancer diagnosis, the nondisclosure practice by health care professionals in Egypt needs to be changed. This should be within the context of respecting patients’ autonomy and responding to their preferences. Such change may not be easy in cultures resistant to honest disclosure and factors related to health care professionals, patients, and their families that contribute to the nondisclosure practice should be taken into consideration. In Egypt, a minority of cancer patients’ family caregivers are still against the honest disclosure of cancer diagnosis which represents a barrier to patient-centered cancer care. Accepting the nondisclosure request of these family caregivers would deprive patients from their right to know their cancer diagnosis. Physicians in Egypt should initiate discussions with family caregivers to explore the reason behind their nondisclosure request and use the current evidence as a tool to change their negative attitude.

The current study has limitations including the purposive sampling method and the use of an abbreviated QoL assessment tool that did not allow for exploring different aspects of QoL. An abbreviated questionnaire was used for the easier administration in the busy study sites. Furthermore, comprehension of the word malignant was not tested, and actual discussion with patients about their disease, especially illiterates, was not explored.

In conclusion, the results of the current study add to the evidence that unawareness of cancer diagnosis is not associated with less psychological burden or better QoL in patients with cancer.

### AFFILIATIONS

1. Palliative Medicine Unit, Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt
2. Clinical Oncology Department, Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt
3. Damietta Cancer Center, Damietta, Egypt
4. JCO Global Oncology

### CORRESPONDING AUTHOR

Samy A. Alsirafy, MBBCh, MSc, MD, Palliative Medicine Unit, Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine, King Abdul-Aziz Al-Saud St, Cairo, 11562, Egypt; e-mail: alsirafy@kasralainy.edu.eg.

### EQUAL CONTRIBUTION

S.A.A. and H.I.A.-A. contributed equally to this work.

### TABLE 4. Anxiety and Depression Categories and Their Relationship to Quality of Life and Cancer Diagnosis Awareness

| HADS       | All Patients No. (%) | Median (IQR) | P \(^a\) | FACT-G7 | Cancer Diagnosis Awareness |
|------------|----------------------|--------------|---------|---------|----------------------------|
|            |                      |              |         | Unaware No. (%) | Aware No. (%) | P \(^b\) |
| HADS-Anxiety |                     |              |         |          |                            |        |
| Normal     | 165 (56.5)           | 18 (15.0-21.0)| <.0001  | 54 (56.8) | 111 (56.3) | .696 |
| Borderline | 46 (15.8)            | 16 (11.3-20.7)|         | 17 (17.9) | 29 (14.7)  |        |
| Abnormal   | 81 (27.7)            | 11 (7.8-14.0) |         | 24 (25.3) | 57 (28.9)  |        |
| HADS-Depression |                  |              |         |          |                            |        |
| Normal     | 138 (47.3)           | 19.8 (16.0-22.0) | <.0001  | 44 (46.3) | 94 (47.7)  | .735 |
| Borderline | 60 (20.5)            | 16 (11.0-19.0) |         | 22 (23.2) | 38 (19.3)  |        |
| Abnormal   | 94 (32.2)            | 11 (8.0-13.0)  |         | 29 (30.5) | 65 (33.0)  |        |

Abbreviations: FACT-G7, Functional Assessment of Cancer Therapy-General 7; HADS, Hospital and Anxiety Depression Scale; IQR, interquartile range.

\(^a\)Kruskal-Wallis test.

\(^b\)Chi-square test.
AUTHOR CONTRIBUTIONS

Conception and design: Samy A. Alsirafy, Hadeer I. Abdel-Aziz, Hesham H. Abdel-Aal, Wessam A. El-Sherief
Administrative support: Hesham H. Abdel-Aal, Wessam A. El-Sherief
Provision of study materials or patients: Hadeer I. Abdel-Aziz
Collection and assembly of data: Hadeer I. Abdel-Aziz, Dina E. Farag
Data analysis and interpretation: Samy A. Alsirafy, Hadeer I. Abdel-Aziz

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/go/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Wessam A. El-Sherief

Speakers’ Bureau: Merck
Travel, Accommodations, Expenses: Roche

No other potential conflicts of interest were reported.

REFERENCES

1. Alsirafy SA, Abdel-Kareem SS, Ibrahim NY, et al: Cancer diagnosis disclosure preferences of family caregivers of cancer patients in Egypt. Psychooncology 26:1758-1762, 2017
2. Ni YH, Alræk T: What circumstances lead to non-disclosure of cancer-related information in China? A qualitative study. Support Care Cancer 25:811-816, 2017
3. Tuckett AG: Truth-telling in clinical practice and the arguments for and against: A review of the literature. Nurs Ethics 11:500-513, 2004
4. Jiang Y, Liu C, Li JY, et al: Different attitudes of Chinese patients and their families toward truth telling of different stages of cancer. Psychooncology 16:928-936, 2007
5. Rao A, Ekstrand M, Heylen E, et al: Breaking bad news: Patient preferences and the role of family members when delivering a cancer diagnosis. Asian Pac J Cancer Prev 17:1779-1784, 2016
6. Abdel-Hafeez A, Abdel-Aziz HI, Hassaan A, et al: Diagnosis disclosure preferences of cancer patients in Egypt: A multi-institutional cross-sectional study. Am J Hosp Palliat Med. 10.1177/10499091211041082 [epub ahead of print on August 24, 2021]
7. Kirklin D: Truth telling, autonomy and the role of metaphor. J Med Ethics 33:11-14, 2007
8. Husson O, Mols F, van de Poll-Franse LV: The relation between information provision and health-related quality of life, anxiety and depression among cancer survivors: A systematic review. Ann Fam Med 22:761-772, 2011
9. Shahid J: Not telling the truth: Circumstances leading to concealment of diagnosis and prognosis from cancer patients. Eur J Cancer Care (Engl) 19:589-593, 2010
10. Alexander PJ, Dinesh N, Vidyasagar MS: Psychiatric morbidity among cancer patients and its relationship with awareness of illness and expectations about treatment outcome. Acta Oncol 32:623-626, 1993
11. Annunziata MA, Fialadore S, Magri MD, et al: Does the information level of cancer patients correlate with quality of life? A prospective study. Tumori 84:619-623, 1998
12. Chandra PS, Chaturvedi SK, Kumar A, et al: Awareness of diagnosis and psychiatric morbidity among cancer patients—A study from South India. J Psychosom Res 45:257-261, 1998
13. Atesci FC, Baltaliarli B, Oguzmanoglu NK, et al: Psychiatric morbidity among cancer patients and awareness of illness. Support Care Cancer 12:161-167, 2004
14. Tavoli A, Mohagheghi MA, Montazeri A, et al: Anxiety and depression in patients with gastrointestinal cancer: Does knowledge of cancer diagnosis matter? BMC Gastroenterol 7:28, 2007
15. Wang DC, Guo CB, Peng X, et al: Psychological morbidity and health-related quality of life in patients with differing awareness of cancer diagnosis: A cross-sectional study. Psychooncology 23:975-980, 2014
16. Chittem M, Norman P, Harris PR: Illness representations and psychological distress in Indian patients with cancer: Does being aware of one’s cancer diagnosis make a difference? Psychooncology 24:1694-1700, 2015
17. Qian H, Hou L: Psychological impact of revealing a diagnosis of lung cancer to patients in China. J Thorac Dis 8:2879-2884, 2016
18. Zigmund AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361-370, 1983
19. Bell ML, Fairclough DL, Fierro MH, et al: Handling missing items in the Hospital Anxiety and Depression Scale (HADS): A simulation study. BMC Res Notes 9:479, 2016
20. Terkawi AS, Al-Hanaqta M, Alshraideh H, et al: Quality of life and psychological well-being of breast cancer survivors in Jordan. Asian Pac J Cancer Prev 15:5927-5936, 2014
21. Yanez B, Pearman T, Lis C, et al: The FACT-G7: A rapid version of the functional assessment of cancer therapy-general (FACT-G) for monitoring symptoms and concerns in oncology practice and research. Ann Oncol 24:1073-1078, 2013
22. Dhand NK, Khatkar MS: Statulator: An Online Statistical Calculator. Sample Size Calculator for Comparing Two Independent Means. 2014. http://statulator.com/SampleSize/ss2M.html
23. Abu-Helalah M, Al-Hanaqta M, Alshraideh H, et al: Quality of life and psychological well-being of breast cancer survivors in Jordan. Asian Pac J Cancer Prev 15:5927-5936, 2014

OTHER REFS

1. Shahidi J: Not telling the truth: Circumstances leading to concealment of diagnosis and prognosis from cancer patients. Eur J Cancer Care (Engl) 19:589-593, 2010
2. Ni YH, Alræk T: What circumstances lead to non-disclosure of cancer-related information in China? A qualitative study. Support Care Cancer 25:811-816, 2017
3. Tuckett AG: Truth-telling in clinical practice and the arguments for and against: A review of the literature. Nurs Ethics 11:500-513, 2004
4. Jiang Y, Liu C, Li JY, et al: Different attitudes of Chinese patients and their families toward truth telling of different stages of cancer. Psychooncology 16:928-936, 2007
5. Rao A, Ekstrand M, Heylen E, et al: Breaking bad news: Patient preferences and the role of family members when delivering a cancer diagnosis. Asian Pac J Cancer Prev 17:1779-1784, 2016

© 2022 by American Society of Clinical Oncology